SHOX2 and cancer: Hence, it is likely that SHOX2 and SEPT9 are methylated in several different malignancies and represent promising pan cancer biomarkers in clinical questions where the discrimination between malignant and benign disease irrespective of any specificity regarding the origin of a malignant tumor is desired.